Date:5/9/2008

ot obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at http://www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.

GENAERA CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share data)

Three Months Ended

March 31,

2008 2007

Revenues $ 1,309 $ 207

Costs and expenses:

Resea
'/>"/>

SOURCE Genaera Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Genaera Corporation Announces 2007 Financial Results
2. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
3. Genaera Corporation Announces Third Quarter Financial Results
4. Genaera to Present at Biotech 2007 and BIO InvestorForum
5. Genaera Elects New Board Member and Announces Executive Appointments
6. EUSA Pharma Completes Acquisition Of Cytogen Corporation
7. Pharmos Corporation Reports 2008 First Quarter Results
8. Alsius Corporation to Host First Quarter 2008 Financial Results Conference Call on May 15, 2008
9. Mac-Gray Corporation Announces First-Quarter 2008 Financial Results
10. MannKind Corporation Reports First Quarter Financial Results
11. Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, Eisai Inc.